(4-Morpholin-4-yl-phenyl)-[5-(1,1,3-trioxo-2,3-dihydro-1H-1lambda6-benzo[d]isothiazol-6-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-carbamic acid tert-butyl ester → 6-[8-(4-Morpholin-4-yl-phenylamino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-1,1-dioxo-1,2-dihydro-1lambda6-benzo[d]isothiazol-3-one
Reaction equation
C(OC(=O)[N:7]([C:29]1[CH:34]=[CH:33][C:32]([N:35]2[CH2:40][CH2:39][O:38][CH2:37][CH2:36]2)=[CH:31][CH:30]=1)[C:8]1[C:9]2[N:10]([N:26]=[CH:27][N:28]=2)[C:11]([C:14]2[CH:25]=[CH:24][C:17]3[C:18](=[O:23])[NH:19][S:20](=[O:22])(=[O:21])[C:16]=3[CH:15]=2)=[CH:12][N:13]=1)(C)(C)C>Cl.O1CCOCC1>[N:35]1([C:32]2[CH:33]=[CH:34][C:29]([NH:7][C:8]3[C:9]4[N:10]([N:26]=[CH:27][N:28]=4)[C:11]([C:14]4[CH:25]=[CH:24][C:17]5[C:18](=[O:23])[NH:19][S:20](=[O:22])(=[O:21])[C:16]=5[CH:15]=4)=[CH:12][N:13]=3)=[CH:30][CH:31]=2)[CH2:40][CH2:39][O:38][CH2:37][CH2:36]1Participants
4
Reactant 1
Product 1
Reagents, catalysts & solvents 2
Procedure
A suspension of (4-morpholin-4-yl-phenyl)-[5-(1,1,3-trioxo-2,3-dihydro-1H-1 λ6-benzo[d]isothiazol-6-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-carbamic acid tert-butyl ester (100 mg, 0.173 mmol) in 4M HCl (2.5 mL) in dioxane is stirred at room temperature for 2 hours. The solvent is removed under vacuum and the residue is triturated with DCM, diethyl ether and petroleum ether to afford the title compound (84 mg, 100%). 1H-NMR (400 MHz, d6-DMSO) δ(ppm) 3.25 (4H, m), 3.85 (4H, m), 7.20 (2H, d), 7.88 (2H, d), 8.16 (1H, d), 8.24 (1H, s), 8.58 (1H, d), 8.82 (2H, s), 8.96 (1H, s), 10.31 (1H, s). LCMS: Rt 2.31 min (95.7%), m/z (APCI) 478 (M+H)+.
Workup
- customThe solvent is removed under vacuum
- customthe residue is triturated with DCM, diethyl ether and petroleum ether
Sources & evidence
- ORD record
- ord-2a87de850dfd4c0298869c44948ccf9e
- Source dataset
- uspto-grants-2009_03
- Patent number
- US07501411B2
Reaction notes
Loading…